The aim of this prospective, contralateral, randomized, double-blind, placebo-controlled study is the evaluation of the performance of a fixed combination of dexpanthenol and hyaluronic acid preservative-free eye artificial tears eye drops, in corneal wound healing after trans epithelial photorefractive keratectomy. One eye of each patient, randomly determined, will be assigned to receive artificial tears containing a combination of dexpanthenol-hyaluronic acid (study group) while the fellow eye will receive Placebo / identical combination containing the same ingredients and hyaluronic acid without dexpanthenol (control group). The drops will be applied hourly postoperatively, starting one hour after the surgery. All subjects will be treated until the day of complete reepithelialization or a maximum of 7 days postoperatively. Researchers will compare the epithelialization between the two eyes. The primary endpoint is the time to reepithelialization.The secondary endpoints are the intra-individual differences measured in each eye in terms of epithelial defect size in each visit, subjective evaluation of pain (discomfort) and subjective evaluation of vision.
Male and female subjects aged ≥ 18
Bilateral trans PRK for the correction of myopia using the Schwind Amaris 1050RS laser at the same treatment zone (6.5mm)
Signed written informed consent Ability and willingness to participate in all examinations
Known hypersensitivity or intolerance to any component of the product
Previous refractive surgery
Myopic refractive error higher than 8.00 diopters (D)
Anisometropia higher than 2.00 D
Parallel
dexpanthenol and hyaluronic acid preservative-free eye artificial tears eye drops
DrugSubjects will receive 1 drop of a hyaluronic acid preservative-free eye artificial tears eye drops (HA) as PLACEBO hourly during the day, but at least 12 times a day, until complete reepithelialization. Composition: 1 ml contains Sodium Hyaluronate 0.15 %, Sodium Chloride, Sodium Citrate, Citric Acid, Water for Injections Dosage Form: Single-dose container (0.5 mL)
Placebo
DrugSubjects will receive 1 drop of a hyaluronic acid preservative-free eye artificial tears eye drops (HA) as PLACEBO hourly during the day, but at least 12 times a day, until complete reepithelialization. Composition: 1 ml contains Sodium Hyaluronate 0.15 %, Sodium Chloride, Sodium Citrate, Citric Acid, Water for Injections Dosage Form: Single-dose container (0.5 mL)
Time to reepithelialization.
The primary endpoint is the time to reepithelialization. Slitlamp biomicroscopy will be preformed to evaluate the integrity of the corneal media and objectively assess epithelial healing with the use of fluoroscein staining. Α record of the time needed until no staining is present will be made.
Epithelial defect size in each visit
Epithelial defect size at each visit measured by slitlamp biomicroscopy The integrity of the corneal media is calculated from the remaining area (A) of the epithelial defects using the following equation: A=π {(α +b) /4}2 where a is the shortest dimension of the defect and b is the longest dimension.
Subjective evaluation of pain (discomfort)
Pain scores will be evaluated using a questionnaire on a scale of 0 to 4 as follows: * 0 as no discomfort or pain * 1 as mild discomfort * 2 as moderate burning pain * 3 as burning pain requiring oral medication (nimesulide 100 mg) * 4 as severe constant or sharp pain not mitigated with oral medication.
Subjective evaluation of vision
Uncorrected distance visual acuity measured using logMAR ETDRS charts at 4 m
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
